Milestone Pharmaceuticals (MIST – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst on January 19. Analyst Patrick Trucchio from H.C. Wainwright remains neutral on the stock and has a $25.00 price target.
Patrick Trucchio’s rating is based on a combination of Milestone Pharmaceuticals’ promising clinical development strategy and the perceived overreaction of the market to recent regulatory setbacks. Trucchio’s confidence in the company’s management and the clinical data for their lead compound, etripamil, suggests that the recent decline in the company’s stock price is excessive. His analysis indicates that, despite the FDA’s refusal to file letter, a new study is unlikely to be requested, and assuming Milestone can address the FDA’s concerns, approval and subsequent product launch could take place by the second half of 2025, aligning with their projections.
Furthermore, Trucchio has utilized a discounted cash flow valuation method that factors in various probabilities of success for etripamil in different medical indications, alongside considerations of potential equity raises to support Milestone’s operations. Despite potential risks including clinical development, market competition, and capital dilution, his assessment yields a firm value that supports a price target of $25 for MIST shares. This valuation, coupled with the expected regulatory progress, underpins the Buy rating assigned to Milestone Pharmaceuticals.
MIST’s price has also changed dramatically for the past six months – from $3.350 to $1.400, which is a -58.21% drop .
See the top stocks recommended by analysts >>
TipRanks tracks over 100,000 company insiders, identifying the select few who excel in timing their transactions. By upgrading to TipRanks Premium, you will gain access to this exclusive data and discover crucial insights to guide your investment decisions. Begin your TipRanks Premium journey today.
Milestone Pharmaceuticals (MIST) Company Description:
Milestone Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the development and commercialization of novel small molecule therapeutics based on clinically-validated mechanisms for the treatment of cardiovascular diseases. It designs and develops a rapid-onset nasal spray with Etripamil. The company was founded by Philippe Douville and Philippe Lamarre in 2005 and is headquartered in Montreal, Canada.
Read More on MIST:
- Biotech Alert: Searches spiking for these stocks today
- Milestone Pharmaceuticals price target lowered to $9 from $17 at TD Cowen
- Milestone Pharmaceuticals to resume trading at 7:30 am ET
- Milestone Pharmaceuticals Receives Refusal to File Letter from U.S. FDA for New Drug Application for Etripamil in the Treatment of PSVT
- Milestone Pharmaceuticals’ etripamil spray New Drug Application refused by FDA
